Extracellular matrix protein accumulation

Extracellular matrix (ECM) protein accumulation refers to the excessive and pathological deposition of structural proteins, such as collagen, fibronectin, and laminin, within the interstitial spaces of organs. This process is the hallmark of fibrosis, a condition where normal tissue is replaced by permanent scar tissue, leading to organ dysfunction and eventually failure in the lungs, liver, kidneys, and heart (Wynn, 2008, PubMed). Under physiological conditions, ECM turnover is a balanced process of synthesis and degradation; however, chronic inflammation or repetitive injury can cause an imbalance where myofibroblasts overproduce matrix components (Bonnans et al., 2014, Nature Reviews Molecular Cell Biology). Although 'ECM protein accumulation' is a descriptive term for a disease state rather than a single molecular target, it is a primary focus of drug development. Current therapeutic strategies aim to disrupt the pathways leading to this accumulation, such as the TGF-beta signaling cascade or the activity of cross-linking enzymes like lysyl oxidase-like 2 (LOXL2), to arrest or reverse the progression of fibrotic diseases.

Other names

ECM accumulationFibrosisExcessive ECM depositionPathological scarring

Pharmacological intervention typically targets upstream signaling pathways (e.g., TGF-beta signaling), inhibits myofibroblast activation, or blocks enzymes responsible for ECM cross-linking (e.g., LOXL2) to reduce the synthesis and deposition of matrix proteins.